Whether ACE inhibitor and/or ARB use is clearly beneficial, neutral, or deleterious in the context of COVID-19-induced pneumonia remains to be seen, and this represents a significant gap in the literature that some have described as a possible “double-edged sword” [198,199]. The gene discussed is ACE; the disease is COVID-19.